Startling news emerged on May 19, 2014 with an ominous report issued from the Pancreatic Cancer Action Network. The report has predicted that pancreatic cancer will become the #2 cause of cancer deaths in the year 2030, bumping colorectal cancer to the third slot. This sobering information comes in response to recent changes in American demographics, such as a larger number of people living past age 65. Additionally, pancreatic cancer affects African Americans in greater numbers, and changes in the U.S. racial demographic will lead to more minority cases of this deadly cancer. The Pancreatic Cancer Action Network is urging preparation for the future rise in cases of pancreatic cancer, such as research and development of pharmaceutical treatments and the development of a screening tool to fight this silent killer. There is currently no distinct screening method for pancreatic cancer and the vast majority of patients have no idea they are harboring this destructive disease until it is too late. An extremely low survival rate is pervasive among patients with pancreatic cancer. Approximately 94 percent of patients diagnosed with this virulent condition will not survive beyond five years. While breast, lung and prostate cancers are still projected to be the top three cancer diagnoses in the year 2030, the prediction of pancreatic cancer to become second deadliest in America in less than twenty years is frightening and urgent.
The full text from the Pancreatic Cancer Action Network’s report was disseminated in the journal Cancer Research on June 1, 2014, although research and development teams are not waiting for the report or the prediction to come to fruition before commencing their needed work. There are several APIs that are currently used to treat pancreatic cancer, and LGM Pharma is a quality provider of these products:
|Erlotinib, also known as the brand name Tarceva is an EGFR inhibitor that has proven to be effectual for patients suffering from pancreatic and lung cancer. This potent drug is regularly used concomitantly with Gemcitabine for metastatic pancreatic cancer and has proven to offer additional time to patients with this unresectable cancer. The common dosage for adult patients is 100 milligrams, taken on an empty stomach once a day.|
|Mitomycin, known as the brand name Mitosol, is sometimes called Mitomycin C. This formidable drug is part of the chemotherapy drugs known as antibiotics, but Mitomycin is actually an alkylating agent. Mitomycin works by stopping the cells in the body from making DNA, resulting in cell death and slowing the progression and symptoms of pancreatic cancer. This effective medication is used as a first line chemotherapeutic agent for treating pancreatic cancer, anal cancer and rectal cancer. Mitomycin is administered via an intravenous infusion every six to eight weeks.|
|Paclitaxel, also known as the brand name Abraxane, was given the official indication as a first-line treatment for patients with metastatic pancreatic cancer in September 2013. The FDA granted this new indication last year based on positive study data from a main clinical trial in which patients were dosed with both Paclitaxel and Gemcitabine. The addition of several months additional life time gleaned in the study gave just cause for the FDA to approve Paclitaxel as a first line treatment. The administration of Paclitaxel is done intravenously with 100 mg of powder which needs to be reconstituted.|
LGM Pharma provides APIs Erlotinib, CAS # 183321-74-6, Paclitaxel, CAS # 33069-62-4 and the TEVA API Mitomycin, CAS # 50-07-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.